Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A

SSSE:603168
4.88
CNY
-0.15
(-2.98%)
-0.89EPS
2.25BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A carries a market capitalization of 2.25B, placing it among publicly traded companies globally. Its enterprise value stands at 2.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.25B
Enterprise Value2.40B

Share Statistics

As of September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A has 372.51M shares outstanding.

Shares Outstanding372.51M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 5.51, and the price-to-book ratio stands at 1.75.

PS Ratio5.51
PB Ratio1.75
P/TBV Ratio2.46

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 5.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.40B versus a market cap of 2.25B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.88

Financial Position

As of September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.55, indicating elevated leverage, while an interest coverage ratio of -45.13 demonstrates limited ability to service its debt obligations.

Current Ratio0.79
Quick Ratio0.41
Debt / Equity23.55
Debt / EBITDA-0.92
Interest Coverage-45.13

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 357,845.03 in revenue per employee across its workforce of 1,142.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee357,845.03
Employee Count1,142.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A recorded 906,755.85 in income tax expense. The company reported a pretax loss of -330.78M and -331.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax906,755.85

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A's stock has declined approximately 41.97% over the past 52 weeks. The 50-day moving average sits at 5.63, while the 200-day moving average is 6.07.

52-Week Price Change-41.97%
50-Day Moving Average5.63
200-Day Moving Average6.07

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A generated 408.66M in revenue and converted that into -331.68M in net income, yielding earnings per share of -0.89. EBITDA reached -329.63M, while operating income came in at -58.01M.

Revenue408.66M
Gross Profit154.68M
Operating Income-58.01M
Pretax Income-330.78M
Net Income-331.68M
EBITDA-329.63M
EBIT-329.63M
Earnings Per Share (EPS)-0.89

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A holds 150.43M in cash and equivalents against 302.86M in total debt, resulting in a net debt position of 139.38M. Total book value stands at 1.29B, with working capital of -76.31M providing operational flexibility.

Cash & Cash Equivalents150.43M
Total Debt302.86M
Net Debt139.38M
Equity (Book Value)1.29B
Book Value Per Share3.45
Working Capital-76.31M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-79.11M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A posted a gross margin of 37.85, reflecting its pricing power and cost economics. The operating margin of -14.20 and net profit margin of -81.16 provide insight into operational efficiency.

Gross Margin37.85
Operating Margin-14.20
Pretax Margin-80.94
Profit Margin-81.16
EBITDA Margin-80.66

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of -2.23 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.20, meaning Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.02
Payout Ratio-2.23
Shareholder Yield-0.20

Stock Splits

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A's most recent stock split took place on June 8, 2018 with a 10:13 split ratio.

Last Split Date6/8/2018
Split Ratio10:13

Scores

As of September 30, 2026, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 2.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.91